Biotie and Seikagaku agree to end License Agreement on Biotie's VAP-1 antibody program

02-May-2012 - Finland

Biotie Therapies Corp.  announced that Biotie and Seikagaku Corporation have agreed to terminate their License Agreement on Biotie's VAP-1 antibody program. The license, under which Biotie had granted Seikagaku exclusive rights for development and commercialization of its VAP-1 monoclonal antibody BTT-1023 in Japan, Taiwan, Singapore, New Zealand and Australia, was executed in April 2003 and was built around Seikagaku's expertise in locomotive diseases. The agreement, which also included an option for Biotie's VAP-1 SSAO small molecule inhibitors, has been terminated with immediate effect.

Timo Veromaa, Chief Executive Officer of Biotie commented, "Based on recently generated exciting data in animal models we have re-profiled the VAP-1 antibody program to primarily target fibrotic diseases and this therapeutic focus is no longer aligned with Seikagaku's business strategy. Regaining the Asia-Pacific rights to BTT-1023 gives us the opportunity to build a fully global development strategy in the fibrosis disease area which has a high level of unmet medical need. "

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous